Johnson & Johnson (JNJ) — DEFA14A Filings
All DEFA14A filings from Johnson & Johnson. Browse 1 DEFA14A reports with AI-powered summaries and risk analysis.
DEFA14A Filings (1)
-
J&J to Acquire Ambrx, Boosting Oncology Pipeline with Next-Gen ADCs
— Jan 8, 2024
Johnson & Johnson (JNJ) announced on January 8, 2024, its definitive agreement to acquire Ambrx Biopharma, Inc. (AMAM), a clinical-stage biopharmaceutical compa
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX